Tandem Diabetes Care (TNDM) Expected to Announce Earnings on Wednesday

Tandem Diabetes Care (NASDAQ:TNDM) is expected to issue its Q2 2025 quarterly earnings data after the market closes on Wednesday, August 6th. Analysts expect the company to announce earnings of ($0.40) per share and revenue of $238.39 million for the quarter.

Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings data on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.07). The business had revenue of $234.42 million during the quarter, compared to the consensus estimate of $220.19 million. Tandem Diabetes Care had a negative net margin of 18.71% and a negative return on equity of 57.33%. The business’s revenue was up 22.3% compared to the same quarter last year. During the same period last year, the company posted ($0.65) earnings per share. On average, analysts expect Tandem Diabetes Care to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tandem Diabetes Care Stock Performance

TNDM stock opened at $16.69 on Wednesday. The stock has a market capitalization of $1.11 billion, a PE ratio of -6.00 and a beta of 1.48. Tandem Diabetes Care has a 12-month low of $14.31 and a 12-month high of $47.60. The company has a current ratio of 2.30, a quick ratio of 1.81 and a debt-to-equity ratio of 1.99. The stock’s 50 day simple moving average is $18.60 and its 200 day simple moving average is $22.64.

Institutional Trading of Tandem Diabetes Care

A number of institutional investors and hedge funds have recently made changes to their positions in TNDM. Millennium Management LLC grew its stake in Tandem Diabetes Care by 41.1% during the 1st quarter. Millennium Management LLC now owns 227,585 shares of the medical device company’s stock valued at $4,361,000 after acquiring an additional 66,245 shares in the last quarter. Royal Bank of Canada grew its stake in Tandem Diabetes Care by 30.5% during the 1st quarter. Royal Bank of Canada now owns 211,666 shares of the medical device company’s stock valued at $4,054,000 after acquiring an additional 49,408 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Tandem Diabetes Care by 5.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 712,559 shares of the medical device company’s stock valued at $13,653,000 after acquiring an additional 34,069 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Tandem Diabetes Care by 9.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 193,993 shares of the medical device company’s stock valued at $3,717,000 after acquiring an additional 16,254 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Tandem Diabetes Care during the 1st quarter valued at about $225,000.

Analyst Ratings Changes

A number of equities research analysts have weighed in on TNDM shares. Wells Fargo & Company decreased their target price on shares of Tandem Diabetes Care from $22.00 to $20.00 and set an “equal weight” rating for the company in a research note on Thursday, May 1st. Canaccord Genuity Group upped their price objective on Tandem Diabetes Care from $58.00 to $59.00 and gave the stock a “buy” rating in a research note on Thursday, May 1st. Mizuho started coverage on Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a “neutral” rating and a $20.00 price objective for the company. Piper Sandler reduced their price objective on Tandem Diabetes Care from $36.00 to $30.00 and set an “overweight” rating for the company in a research note on Thursday, May 1st. Finally, Robert W. Baird cut their price target on Tandem Diabetes Care from $33.00 to $24.00 and set a “neutral” rating for the company in a research note on Thursday, May 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $32.71.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.